Bajaj Healthcare sets Sept 14 record date for ₹1.50 final dividend
- Bajaj Healthcare fixes September 14, 2026, as record date for ₹1.50 per share final dividend
- FY26 revenue rises 12.6% YoY to ₹611.03 crore driven by strong overseas performance
- Net profit drops 50.4% to ₹213.10 crore due to ₹332.47 crore one-time exceptional loss
- EBITDA grows 9.9% to ₹111.95 crore while margin contracts 45 bps to 18.32%
- Debt-equity ratio improves to 0.47 times from 0.51 times in prior year
*this image is generated using AI for illustrative purposes only.
Bajaj Healthcare has fixed September 14, 2026, as the record date for its proposed final dividend of ₹1.50 per equity share for FY26. The payout represents a 30% dividend on the face value of ₹5.
The Mumbai-based pharmaceutical manufacturer reported a 12.6% year-on-year rise in revenue to ₹611.03 crore for FY26, driven by strong overseas performance. However, net profit fell 50.4% to ₹213.10 crore due to a significant one-time exceptional loss.
The Company held its 33rd Annual General Meeting on September 21, 2026, where shareholders approved the adoption of the audited financial statements for the fiscal year ended March 31, 2026. The Board also recommended the final dividend, which will be paid to shareholders whose names appear in the Register of Members or depository records as beneficial owners on the record date.
Financial Performance
Revenue from operations grew from ₹542.60 crore in FY25 to ₹611.03 crore in FY26. EBITDA increased by 9.9% to ₹111.95 crore, reflecting improved operating performance and higher export sales. Despite this top-line growth, the EBITDA margin contracted by 45 basis points to 18.32% from 18.77% in the previous year.
Profit before tax (PBT) before exceptional items rose 35.1% to ₹62.17 crore, supported by a 20.3% decline in finance costs to ₹22.23 crore. This reduction in interest expense was primarily attributable to lower levels of cash credit and working capital loans.
| Metric | FY26 | FY25 | Change |
|---|---|---|---|
| Revenue | ₹611.03 crore | ₹542.60 crore | +12.6% |
| EBITDA | ₹111.95 crore | ₹101.83 crore | +9.9% |
| EBITDA Margin | 18.32% | 18.77% | -45 bps |
| Net Profit | ₹213.10 crore | ₹429.29 crore | -50.4% |
What the Numbers Show
The divergence between robust operational growth and declining bottom-line profitability was driven entirely by non-recurring items. The Company recognized a one-time exceptional loss of ₹332.47 crore during the year. This charge resulted from the reversal of income previously recognized under a transfer of technical know-how arrangement with a Middle East-based customer. Due to regional instability, the customer failed to meet committed timelines, necessitating the reversal. Without this exceptional item, PBT would have grown significantly, highlighting that the core operational engine remains healthy despite the headline profit decline.
Balance Sheet and Capital Structure
The Company strengthened its equity base through the conversion of warrants into equity shares, raising approximately ₹52.71 crore. This capital infusion, alongside debt repayments, reduced the debt-equity ratio to 0.47 times from 0.51 times in FY25.
Net worth expanded by 14.3% to ₹533.00 crore. Cash and cash equivalents surged to ₹37.24 crore from ₹2.60 crore in the prior year, bolstered by operating cash flows of ₹58.08 crore. Trade receivables improved to 140 days of sales from 169 days, indicating better collection efficiency despite revenue growth.
Strategic Developments
During FY26, Bajaj Healthcare continued its transition toward specialized molecules and formulation capabilities. The Company acquired Genrx Pharmaceuticals Private Limited through the insolvency resolution process to strengthen its formulation portfolio, though the facility remains pending tribunal approvals. R&D expenditure doubled to ₹13.15 crore (2.2% of revenue), supporting pipeline development in oncology and complex generics.
Historical Stock Returns for Bajaj HealthCare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.67% | -0.83% | +2.32% | +18.82% | -23.73% | -8.93% |
How will the pending tribunal approvals for the Genrx Pharmaceuticals acquisition impact Bajaj Healthcare's timeline for integrating its new formulation capabilities?
Given the reversal of income due to Middle East regional instability, what risk mitigation strategies is the company implementing for its other overseas contracts in volatile markets?
With R&D expenditure doubling to 2.2% of revenue, which specific oncology or complex generic molecules are expected to reach commercialization in the next 12-18 months?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
